Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04589299 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)

Study acronym: SIDEC
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2030
    • Secondary endpoints: details revised at 1 of 13 entries
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
SIDEC - (Subcutaneous Immunoglobulin in De-novo CIDP) ia a study designed as a randomized, parallel study with an open-label extension phase. The aims are to compare the effect of SCIG and IVIG in 60 treatment-naïve CIDP patients, and to detect the lowest effective dosage for maintenance treatment.
Trial Details
NCT Number NCT04589299
Lead Sponsor University of Aarhus
Collaborators: Rigshospitalet, Denmark, Aarhus University Hospital, Odense University Hospital, Aalborg University Hospital
Conditions
(from sponsor)		 CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Related terms Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov